XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Patent and Technology License Agreements (Details) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Oct. 06, 2020
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2022
Sep. 30, 2021
Patent and Technology License Agreements [Line Items]              
Annual maintenance fee expense         $ 90,000 $ 90,000  
Annual minimum royalty payment       $ 100,000      
Increasing annual royalties       25,000      
Maximum aggregate annual royalties       150,000      
Payable amount to NAT       1,100,000      
Research and development expense   $ 3,605,898 $ 4,726,855 6,227,808 $ 8,172,370    
Obligated pay amount   $ 51,000,000   $ 51,000,000      
Revenue percentage   50.00%   50.00%      
Upfront payment       $ 40,000,000      
Commercial milestone payments       $ 300,000,000      
Net sales percentage       50.00%      
Description of license agreement       The term of the license agreement will continue until (i) if there has not been a commercial sale of a licensed product in the territory, the 10-year anniversary of the original license effective date, March 30, 2016, or (ii) if there has been a first commercial sale of a licensed product in the territory within the 10-year anniversary of the original license effective date, the 10-year anniversary of the first commercial sale on a country-by-country basis. The term of the license may be extended for additional 10-year periods for all countries in the territory by notifying Eisai and paying an extension fee equal to $10 million.      
License Agreement [Member]              
Patent and Technology License Agreements [Line Items]              
License agreement development, description       Under the license agreement, Eisai is to receive a $6.0 million development milestone payment upon initial approval and additional commercial milestone payments related to the achievement of net product sales thresholds (which increases to $7 million in the event we have exercised our option to add India to the licensed territory prior to FDA approval) and an aggregate of up to $22 million related to the achievement of net product sales thresholds. Citius Oncology was required to reimburse Eisai for up to $2.65 million of its costs to complete the Phase 3 pivotal clinical trial for LYMPHIR for the CTCL indication and reimburse Eisai for all reasonable costs associated with the preparation of a Biologics License Application (“BLA”) for LYMPHIR.      
NoveCite [Member]              
Patent and Technology License Agreements [Line Items]              
Research and development expense             $ 5,000,000
Outstanding equity 25.00%            
Percentage of outstanding equity 75.00%            
Percentage of ownership additional shares 25.00%            
Minimum [Member]              
Patent and Technology License Agreements [Line Items]              
Development milestone payments       $ 40,000,000      
Percentages of net product sales       10.00%      
Minimum [Member] | Royalties [Member]              
Patent and Technology License Agreements [Line Items]              
Percentages of net product sales       10.00%      
Maximum [Member]              
Patent and Technology License Agreements [Line Items]              
Development milestone payments       $ 70,000,000      
Percentages of net product sales       15.00%      
Maximum [Member] | Royalties [Member]              
Patent and Technology License Agreements [Line Items]              
Percentages of net product sales       15.00%